Historical Valuation
Estrella Immunopharma Inc (ESLA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -0.57. The fair price of Estrella Immunopharma Inc (ESLA) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：1.20
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Estrella Immunopharma Inc (ESLA) has a current Price-to-Book (P/B) ratio of -5.34. Compared to its 3-year average P/B ratio of 28.90 , the current P/B ratio is approximately -118.46% higher. Relative to its 5-year average P/B ratio of 23.50, the current P/B ratio is about -122.71% higher. Estrella Immunopharma Inc (ESLA) has a Forward Free Cash Flow (FCF) yield of approximately -2.08%. Compared to its 3-year average FCF yield of -24.46%, the current FCF yield is approximately -91.50% lower. Relative to its 5-year average FCF yield of -24.46% , the current FCF yield is about -91.50% lower.
P/B
Median3y
28.90
Median5y
23.50
FCF Yield
Median3y
-24.46
Median5y
-24.46
Competitors Valuation Multiple
AI Analysis for ESLA
The average P/S ratio for ESLA competitors is 0.54, providing a benchmark for relative valuation. Estrella Immunopharma Inc Corp (ESLA.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for ESLA
1Y
3Y
5Y
Market capitalization of ESLA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ESLA in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ESLA currently overvalued or undervalued?
Estrella Immunopharma Inc (ESLA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -0.57. The fair price of Estrella Immunopharma Inc (ESLA) is between to according to relative valuation methord.
What is Estrella Immunopharma Inc (ESLA) fair value?
ESLA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Estrella Immunopharma Inc (ESLA) is between to according to relative valuation methord.
How does ESLA's valuation metrics compare to the industry average?
The average P/S ratio for ESLA's competitors is 0.54, providing a benchmark for relative valuation. Estrella Immunopharma Inc Corp (ESLA) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Estrella Immunopharma Inc (ESLA) as of Jan 10 2026?
As of Jan 10 2026, Estrella Immunopharma Inc (ESLA) has a P/B ratio of -5.34. This indicates that the market values ESLA at -5.34 times its book value.
What is the current FCF Yield for Estrella Immunopharma Inc (ESLA) as of Jan 10 2026?
As of Jan 10 2026, Estrella Immunopharma Inc (ESLA) has a FCF Yield of -2.08%. This means that for every dollar of Estrella Immunopharma Inc’s market capitalization, the company generates -2.08 cents in free cash flow.
What is the current Forward P/E ratio for Estrella Immunopharma Inc (ESLA) as of Jan 10 2026?
As of Jan 10 2026, Estrella Immunopharma Inc (ESLA) has a Forward P/E ratio of -2.24. This means the market is willing to pay $-2.24 for every dollar of Estrella Immunopharma Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Estrella Immunopharma Inc (ESLA) as of Jan 10 2026?
As of Jan 10 2026, Estrella Immunopharma Inc (ESLA) has a Forward P/S ratio of 0.00. This means the market is valuing ESLA at $0.00 for every dollar of expected revenue over the next 12 months.